Guoliang Hao completed his Doctoral degrees (PhD) at the University of Manchester in 2012. Then he moved to the Department of Physiology, Anatomy and Genetics (DPAG) at the University of Oxford, worked in the laboratory of Prof David Paterson and Prof Neil Herring as a postdoctoral research fellow. In 2017, Guoliang founded Beijing SCOPE Ltd. and the SCOPE Research Institute of Electrophysiology in China, where he leads a world-leading cardiac electrophysiology research team. In addition, he was appointed as a University Professor at the Heart Center of the First Affiliated Hospital of Xinxiang Medical University, China (2022).
Guoliang’s main research focuses on the physiological mechanism of cardiac arrhythmias, the development of antiarrhythmic drugs, and the preclinical cardiac safety evaluation of drugs. His team has developed the most sophisticated preclinical cardiac mapping technologies (electrical mapping & optical mapping) for various cardiac tissues, ranging from the whole heart to iPSC-cardiomyocyte. These mapping technologies not only allow researchers to pinpoint the exact areas of diseased tissue/cells with abnormal electrical conductivity, but also provide a massive output of relevant electrophysiological parameters. The applications include cardiotoxicity screening, myocardial infarction, cardiac regeneration, atrial/ventricular fibrillation. The mapping technologies have been widely applied and highly recognized in more than 100 cardiac research groups around the world. Guoliang’s team has also established a long-term collaboration with Prof David Paterson at DPAG.